Product Program year 2024 Source: CMS Open Payments

Locametz

Drug Oncology

NDC 69488-017-61

Open in the dashboard

General payments

$3,822

165 payments

Research payments

$18,505

33 payments

Through program year 2024, $3,822 in general payments and $18,505 in research payments were reported against Locametz (Oncology).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

3 rows
Year Kind Amount Payments
2024 General $240 12
2024 Research $18,505 33
2023 General $3,582 153

Breakdown

Who paid General payments · program years 2023–2024
  1. Novartis Pharmaceuticals Corporation $3,822 165 payments
Top recipients General payments · program year 2024
  1. Tse-Kuan Yu Radiation Oncology · Houston, TX $23 10% · 1 payment
  2. Donald Norwood Diagnostic Radiology · Little Rock, AR $22 9% · 1 payment
  3. David Hays Vascular & Interventional Radiology · Little Rock, AR $22 9% · 1 payment
  4. Edgar St Amour Vascular & Interventional Radiology · Little Rock, AR $22 9% · 1 payment
  5. Peter Lindley Diagnostic Radiology · Little Rock, AR $22 9% · 1 payment

The top 5 of 12 recipients; each share is of general payments naming this product in 2024.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2024
  1. Vascular & Interventional Radiology Radiology $65 27% · 3 practitioners
  2. Diagnostic Radiology Radiology $65 27% · 3 practitioners
  3. Nuclear Radiology Radiology $30 13% · 2 practitioners
  4. Radiation Oncology Radiology $23 10% · 1 practitioner
  5. Hematology & Oncology Internal Medicine $19 8% · 1 practitioner

The top 5 of 7 specialties; each share is of general payments naming this product to practitioners with a specialty in 2024. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2024
  1. Arkansas $129 54% · 6 recipients
  2. Louisiana $57 24% · 3 recipients
  3. Ohio $30 13% · 2 recipients
  4. Texas $23 10% · 1 recipient

Each share is of general payments naming this product in 2024 where a state was reported.

165 general · 33 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record